Compare PXLW & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | PSTV |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 27.9M |
| IPO Year | 2000 | 2016 |
| Metric | PXLW | PSTV |
|---|---|---|
| Price | $5.82 | $6.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $14.33 | ★ $55.00 |
| AVG Volume (30 Days) | 32.8K | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | $693,000.00 | ★ $5,213,000.00 |
| Revenue This Year | $47.19 | $13.20 |
| Revenue Next Year | $30.00 | $261.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $0.13 |
| 52 Week High | $15.42 | $8.00 |
| Indicator | PXLW | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 64.92 |
| Support Level | $5.67 | $0.37 |
| Resistance Level | $7.03 | $8.00 |
| Average True Range (ATR) | 0.27 | 0.77 |
| MACD | 0.05 | -0.18 |
| Stochastic Oscillator | 73.53 | 43.95 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).